1. Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations. (October 2022) Authors: Ng, P.Y.; Han, Y.C.; Shin Ogawa, L.; Schulz, R.; Yang, S.N.; Jewett, I.; Ishiyama, N.; Romashko, D.; Salomatov, A.; Thakur, S.; Lucas, M.; Lin, T.A.; Buck, E. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗